Ricardo is Helping to Accelerate Europe’s Transformation to a Climate-resilient Future
Ricardo, a global strategic environmental and engineering consulting company, is leading the EU Mission Implementation Platform for Adaptation to Climate Change (MIP4Adapt), providing support to the European Commission and everyone delivering the EU Mission on Adaptation to Climate Change.
The Mission is focused on supporting European regions and local authorities to accelerate their adaptation to climate change and building climate resilience. This is of vital importance given the fact that the impacts of climate change are already happening, and more regularly – as evidenced by extreme weather events already increasing in magnitude and frequency which are having direct and indirect impacts on our environment, society, and economy. In turn, these impacts may increasingly lead to transnational spill-over effects on international trade, resource competition, regional conflict, migration, and the spread of pests and diseases.
Ricardo’s experts across Europe are working closely with the European Commission in delivering MIP4Adapt – which is the result of a public procurement process - with the work commitment starting in 2023 and running until 2025. MIP4Adapt’s core team also includes experts from: Fresh Thoughts Consulting, Icatalist, the European Federation of Agencies and Regions for Energy and Environment – FEDARENE, and Joanneum Research, as well as experts from across Europe able to deliver technical assistance to the regional and local authorities in all 27 EU Member States.
In leading MIP4Adapt, Ricardo is facilitating the development of a community of practice to promote the exchange of knowledge and experiences and enable regional and local authorities across Europe to strengthen coordination and collaboration around climate adaptation. The community includes the 308 regional and local authorities that are signatories to the Mission Charter, covers approximately 40% of Europe’s land area and population, and is committed to striving towards climate resilience by 2030. In addition, it comprises relevant EU-funded research and innovation projects, the European Commission and other relevant European institutions, national authorities, and Friends of the Mission, including research institutions and businesses.
Through MIP4Adapt, Ricardo is also delivering technical assistance to the regional and local authorities that are Charter signatories. This includes helping them to: develop their climate adaptation plans; identify appropriate climate adaptation demonstration projects; identify and access suitable finance and funding for implementation of their plans and demonstration projects; and stimulate engagement and mobilisation of citizens and stakeholders in climate adaptation.
Richard Smithers, Director of MIP4Adapt and Ricardo’s international lead on climate adaptation said: “Ricardo’s delivery of MIP4Adapt builds upon our support for the European Commission over the last decade regarding development and implementation of the EU Adaptation Strategy. It also draws on Ricardo’s wide-ranging experience of supporting all aspects of climate adaptation planning at all scales in over 40 countries beyond Europe, and on the expertise of our wider team. Through our leadership of MIP4Adapt, our desire is to help to amplify the Mission’s overall impact across mainland Europe, so it is greater than the sum of individual actions.”
Ends
Notes to editors:
About the EU Mission on Adaptation to Climate Change
Further information about the Mission and MIP4Adapt can be found at the Mission Portal, Visit https://climate-adapt.eea.europa.eu/en/mission
About the core team for MIP4Adapt
Ricardo’s core team for MIP4Adapt also includes experts from Fresh Thoughts Consulting (leading access to the best available knowledge, tools and methods in association with the European Environment Agency), Icatalist (leading on stakeholder and citizen engagement), the European Federation of Agencies and Regions for Energy and Environment – FEDARENE (supporting networking between regional and local authorities) and Joanneum Research (fostering links between the EU Mission on Adaptation to Climate Change and the four other EU Missions).
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726541878/en/
Contact information
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 05:35:00 EET | Press release
Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through its partners by the end of October 2025, marking a threefold increase compared to the same period in 2024, with MSMEs among the key segments driving this growth. International Finance Corporation estimates a US$8 trillion financing gap for MSMEs in emerging markets and developing economies. With global platforms, from e-commerce to food delivery, entering emerging markets and local platforms in these markets continue to scale, many are looking to offer tailored credit services to better support MSMEs operating on their ecosystems. Doin
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 05:00:00 EET | Press release
Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in real-time global treasury management. It has already supported a successful H
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo ™ 300mg18.11.2025 04:51:00 EET | Press release
The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These improvements may contribute to an enhanced treatment journey for patients by helping reduce the disease burden they face throughout their care. Given its distinctive product profile, Omlyclo™ 300mg has the potential to become an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
